Skip to main content
Cencora, Inc. logo

Cencora, Inc. — Investor Relations & Filings

Ticker · COR ISIN · US03073E1055 LEI · AI8GXW8LG5WK7E9UD086 US Wholesale and retail trade
Open in API
Filings indexed 1,821 across all filing types
Latest filing 2026-05-29 Board/Management Inform…
Country US United States of America
Listing US COR

About Cencora, Inc.

https://www.cencora.com/

Cencora, Inc., formerly AmerisourceBergen, is a global pharmaceutical solutions organization centered on improving the health of people and animals. The company's core activity is pharmaceutical sourcing and distribution, acting as a key link between manufacturers, healthcare providers, and patients. Cencora offers end-to-end capabilities across the healthcare spectrum, providing solutions that support drug development, enhance patient care in physician practices and clinics, and help pharmacies scale and achieve stronger clinical results. It leverages its global logistics network to ensure therapies are accessible where and when they are needed, connecting partners to facilitate the delivery of medications and innovative treatments worldwide.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 92% confidence The document is a U.S. SEC Form 8-K (“Current Report”) dated May 23, 2026. Item 5.02 of the report details the departure of the incumbent CFO and the appointment of a new Executive Vice President and Chief Financial Officer, including employment agreements and compensatory arrangements. This clearly constitutes an announcement of changes in senior management roles. Under our taxonomy, such filings are classified as Board/Management Information (Code MANG).
2026-05-29 English
SD
Regulatory Filings Classification · 85% confidence The document is an SEC Form SD (“Specialized Disclosure Report”) filed pursuant to Rule 13p-1 covering conflict minerals disclosures for the period January 1–December 31, 2025. It is a mandated compliance/regulatory filing rather than a financial report (10-K, interim, earnings release) or a substantive ESG/sustainability narrative. This type of specialized Form SD is classified under general regulatory filings.
2026-05-29 English
10-Q - Cencora, Inc. (0001140859) (Filer)
Interim / Quarterly Report Q2 2026
2026-05-06 English
8-K - Cencora, Inc. (0001140859) (Filer)
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K current report under the Exchange Act that does not contain substantive financial statements or detailed earnings data itself but rather notifies the SEC and investors that an earnings news release (Exhibit 99.1) and conference call materials have been issued and are available. The text is under 5,000 characters and repeatedly states the earnings release is attached and materials are on the website. This fits the definition of a Report Publication Announcement (RPA) rather than the earnings release itself or a full report.
2026-05-06 English
SCHEDULE 13G/A - Cencora, Inc. (0001140859) (Subject)
Major Shareholding Notification
2026-03-26 English
8-K - Cencora, Inc. (0001140859) (Filer)
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 21, 2026, by Cencora, Inc. It announces a definitive agreement to acquire EyeSouth Partners' retina business, which is a material event requiring current reporting. The document includes a press release as an exhibit and contains forward-looking statements about the transaction. There are no financial statements or detailed financial analysis included, only a disclosure of a significant corporate event (an acquisition agreement). This type of filing is best classified under M&A Activity (TAR) as it relates to merger and acquisition announcements and documents.
2026-03-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.